BBTV

About Us

latest videos

CoNCERT CEO Roger Tung, Interviewed by Eric Schmidt

Wall Street on BioBusiness.TV
  1. CoNCERT’s Leading Portfolio Asset to step into GSK Paroxetine’s $3Bn Shoes
  2. CoNCERT’s IPO, Partnering Strategies and Full Integration for it’s Deuterium Substitution Platform & Pipeline Assets
  3. CoNCERT’s Deuterium Substitution Platform to Create Better, Faster, Cheaper Drugs

Fred Frank on the Jan Buck Show

1. Portrait of Wall Street’s Pioneer Drug Analysts
2. The Future of the Industry, and the Lehman / Barclays Deal.
3. Blockbuster Drugs, and the 3 Eras of the Biotech Industry.

Ablynx CEO Edwin Moses, Interviewed by Geoff Meacham

Wall Street on BioBusiness.TV
  1. Ablynx introduces Nanobody Technologies, discusses Pharma Partnering Strategies
  2. Ablynx’s Pipeline, Technology Advantage over MABs, and Financial Risk
  3. Ablynx’s Antithrombotic Safety and Efficacy Profile, Clinical Development Strategy, and Business Development Objectives

TARG – Targanta CEO Mark Lauchtenberger, Interviewed by Joel Sendek

Wall Street on BioBusiness.TV
  1. Targanta’s Antibiotic Shows Promise, And Overcomes the Challenges it Faced When Previously Developed at Lilly and InterMune
  2. Targanta Attacking $1.2Bn Antibiotic Market with Resistance Adverse Drug, Do-or-Die!
  3. Targanta Confident and Prepared for FDA Panel Review of Lead Compound Oritavancin

ALXA – Alexza CEO Tom King, Interviewed by Ted Tenthoff

Wall Street on BioBusiness.TV
  1. Alexza’s Eulogistic Symphony Deal, Partnering and Sales Strategies, and Cash ’till the Summer of 2010
  2. Alexza’s Staccato: Vaporized Drugs in Multiple Indications, with a Safe and Effective Profile

PARD – Poniard CEO Jerry McMahon, Inerviewed by Mike King

Wall Street on BioBusiness.TV
  1. Poniard’s Platinum Compound for Oncology, A Winning Design for its Clinical Trial
  2. Picoplatin in Colorectal, Prostate, Ovarian Cancer and NSCLC, and Poniard’s Cash Position

NLTX – Nile Therapeutics CEO Peter Strumph, Interviewed by Matt Kaplan

Wall Street on BioBusiness.TV
  1. Nile’s Peptide for Heart Failure to Achieve Superiority through Hemodynamic and Renal Action
  2. Nile’s CD-NP Phase 3 Strategy, and Secondary Pipeline Products, and 8 Person Team

Visionaries: Stelios Papadopoulos

1. Financing, Productivity, and the Cost of Innovation.
2. Biotech in 20 Years, Fundamental Science, Personalized Medicine, and Energy.

Vaccine and Antibody Production from Stem Cells, Vivalis

Vivalis uses Embryonic Stem Cell Technology to Enable Vaccine and Antibody Production. Chicken eggs revolutionized the production of vaccines. Could animal stem cells be the new chicken egg? Vivalis has created a technology platform based on embryonic stem cells that enables the production of vaccines and antibodies. Vivalis’ CSO Majid Mehtali is interviewed by Reni Benjamin, ...

I-Stem, Peschanski’s Stem Cell Technology Platform

  1. Standardizing Ways to Create New Treatments for Under-served Disease Markets, with Stem Cell Technology
  2. Is Europe attractive for stem cell research? Which countries are the most advanced and have the most favorable legislation?
  3. Stem Cell Research Financing, Products, Business Models, and Regulatory Concerns
  4. Will Adult Stem Cells Resolve Our Moral Quandaries? Do They Offer The Same Benefits As Embryonic Stem Cells?
« First...<< Previous234567891011

  • Best of the Web

    • Alzheimer's Disease
    • Antibiotic Resistance
    • Cancer Immunotherapy
    • Cell Therapy
    • Hepatitis C
    • LOL
    • Stem Cells
    • - View All -

  • Series

    • The Stem Cell Review
    • Cancer Immunotherapy

  • Shows

    • Biotech in the Money
    • Wall Street On BBTV
    • Science Breakthrough
    • The Jan Buck Show
    • Special Interview
    • Report on Location

  • Corporate Videos

    • 60sec Pitches
    • Investor Presentations
    • Panorama

  • Store

    • Series Sponsorship
    • Corp. Communications
    • DVDs

  • Acknowlegments

    NASDAQ OMX BIO Nature Medicine William Blair Banc of America Cowen Group JMP Securities JP Morgan Ladenburg Thalmann Lazard Capital Markets Piper Jaffrey
  • ABOUT BIOBUSINESS.TV
  • BioBusiness.TV is the first independent Internet TV Network for biotechnology professionals. We create and syndicate video-based industry focused shows and series that range from scientific breakthroughs, to equity analyst insights, as well as C-level executive and investor interviews on strategy, management, policy, marketing, science and more. We strive to enhance the quality and accessibility of industry video programming, and to deliver information biotechnology professionals can rely on to make sound and informed decisions.
  • PARTNERING WITH BIOBUSINESS.TV
  • If you’ve got great video programs and a growing audience, let BioBusiness.TV help you take it to the next level through our Partner Program. You can reach out to us through our ‘contact us’ page.
  • DISCLAIMER
  • Viewers should verify all claims and do their own due diligence before investing in any securities mentioned on BioBusiness.TV.
  • COPYRIGHT © 2011 BIO BUSINESS TV, INC. All Rights Reserved